We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

By LabMedica International staff writers
Posted on 03 Oct 2023
Print article
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations. Currently, the prostate-specific antigen (PSA) test is the standard method for initial screening. It measures PSA levels—a protein produced by the prostate—and higher levels often flag the need for further testing, like biopsies. The challenge is that elevated PSA levels could be due to various factors, like vigorous exercise or prostate infection, not just cancer. This can lead to unnecessary, invasive biopsies and treatments, which may have adverse side effects. To address this issue, a new blood diagnostic test has been developed to offer a risk score based on clinical and biological biomarkers that can help improve decision-making following a high PSA test result.

Nanostics (Edmonton, AB, Canada) has launched ClarityDX Prostate, a rapid, clinically validated diagnostic test that takes into account multiple factors, including PSA levels. It employs the ClarityDX machine learning platform to offer a more accurate risk score for aggressive prostate cancer. The test is designed to help patients and their healthcare providers decide if a biopsy is needed after getting a high PSA test result. It uses a unique machine-learning algorithm and examines data from two biological and three clinical biomarkers. Since it relies on lab data from an existing PSA blood test, it can be easily incorporated into the current patient care pathway at a low additional cost.

ClarityDX Prostate is particularly useful at the initial diagnosis stage to help decide whether a biopsy is necessary. Studies indicate that adding ClarityDX Prostate to the standard patient care path could reduce unnecessary biopsies by as much as 35%, leading to considerable cost savings. This groundbreaking blood test is a significant step forward in prostate cancer screening. It offers crucial support to men between the ages of 40 and 75 and their doctors in making more informed decisions—three times more accurately—about the need for a biopsy after a high PSA test result.

"This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk," said Dr. John D. Lewis, CEO of Nanostics.

Related Links:

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Procalcitonin Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Glassware Washer
Tiva 10-1ML

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.